Investor Presentaiton

Establishing Leadership Across Key Oncogenic Mutations1 KRAS Prevalence in Tumors With High Unmet Needs (metastatic tumors) Prevalence of Oncogenic Mutations in Metastatic NSCLC 2 NSCLC 2% 14% ■ KRAS G12A 4% ■ KRAS G12C 4% ■ KRAS G12D ■ KRAS G12V KRASG12C 14% KRASG12C MT occur in -14% of NSCLC, comparable to the prevalence of EGFR mutations KRASG12D 4% 3% 4% ■ KRAS G12A CRC 12% ■ KRAS G12C Other EGFR 2% 48% 13% ■ KRAS G12D 9% ■ KRAS G12S ■KRAS G12V Pancreatic ■ KRAS G12D 36% ■ KRAS G12R ■ KRAS G12C ■■KRAS G12V 21% 11% 2% MTAP 10% ALK 5% ROS1 NTRK 1% BRAF METex14 1.5% 2% 3% 1. EGFR and ALK - Decision Resource Group 2022 NSCLC Epidemiology Dashboard; ROS1 - Hirsch FR et al. Lancet 2017; MET exon 14 - Drilon A, et al. J Thorac Oncol. 2017; BRAF- Marchetti A, et al. J Clin Oncol. 2011 NTRK- 2. Internal Mirati epidemiology estimates with inputs from external sources, including Seer Stat and PanCancer Atlas Ill Bristol Myers Squibb Rosen EY, et al. Clin Cancer Res 2020; KRAS G12C - AACR GENIE build v9.6, Clinico-Genomics dataset, Biernacka et al.; MSKSCC Cancer Discover 2017; Araujo et al.; Nassar et al.; Flatiron CGDB; KRASG12D - AACR GENIE build v9.6. Not for Product Promotional Use 15

View entire presentation